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Abstract To study the therapeutic effect of Armillarisin
A on patients with ulcerative colitis (UC) and on serum IL-
1b and IL-4, sixty patients with UC were randomly divided
into three groups: Armillarisin A treatment group (Group
I), Armillarisin-combined hormone therapy group (Group
II), and hormones treatment as the control group (Group
III). Patients in Group I received Armillarisin A 10 mg
enema in 100 ml saline. Patients in Group II received
Armillarisin A 10 mg and dexamethasone 5 mg enema in
100 ml saline. Patients in Group III received only dexa-
methasone 5 mg enema in 100 ml saline. The therapeutic
efficacy and serum levels of IL-4 and IL-1b were observed.
After 4 week treatment, the total effective rates were
90.0 % in Group I and 95.0 % in Group II. Both are higher
than it in control group, which was 70.0 %. The serum
levels of IL-4 in Groups I and II were significantly higher
than it in control group. Compared to IL-4 levels before
treatment, the levels of IL-4 after treatment were signifi-
cantly higher in both Groups I and II. The serum levels of
IL-11b were significantly decreased in Groups I and II in
comparison to it in control group. Compared to the levels
of IL-1b before treatment, the levels of IL-1b were sig-
nificantly decreased. Armillarisin A shows a significant
effect in treating UC. It helps increase IL-4 and lower IL-
1b and the mechanism may be related to the body’s
immunity regulation.
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Introduction
Ulcerative colitis (UC) is an immune-related inflammatory
disease with unknown etiology. The incidence of UC is
continuously increasing in China. Although the pathogen-
esis of UC is not yet clear, most studies suggest that it is
multifactorial. In other words, the combination of internal
and external factors leads to the UC. The factors consist of
genetic factors, inappropriate immune response, and some
certain environmental factors. In recent years, the role of
cytokines in the pathogenesis, development, and prognosis
of UC has been recognized and probably the imbalance
between pro-inflammatory cytokines and anti-inflamma-
tory cytokines plays a key role in the pathogenesis of UC
[1, 2]. Studies have shown that interleukin (IL) plays a
pivotal role during the pathogenesis of UC [3]. In this
study, we investigated the efficacy of Armillarisin on IL-1b
and IL-4 in UC patients.
Materials and Methods
Patient Information
SixtyUCpatients admitted in our hospital from January 2009
to December 2012 were included in this study. Patients were
randomly divided into three groups. Armillarisin treatment
group (Group I) includes 20 patients. Of the 20 patients, 12
are males and 8 are females with age range from 18 to
68 years old. The average is 39.62 ± 11.24 years old. The
courses of disease were among 6 months to 11 years. The
mean is 4.20 ± 4.75 years. Severity grading categorizes
patients to mild 14 cases and moderate 6 cases. Armillarisin-
combined hormone group (Group II) includes 20 patients. Of
the 20 patients, 14 aremales and 6 are femaleswith age range
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from 17 to 69 years old. The average is 38.42 ± 10.54 years
old. The courses of disease were among 5 months and up to
10 years. The mean is 5.20 ± 4.15 years. Severity grading
categorizes patients to mild 13 cases and moderate 7 cases.
Control group with only hormone regiment (Group III)
includes 20 patients. Of the 20 patients, 11 are males and 9
are females with age range from 19 to 70 years old. The
average is 39.62 ± 11.24 years old. The courses of disease
were among 5 months to 10 years. The mean is
5.15 ± 3.75 years. Severity grading categorizes patients to
mild 14 cases and moderate 6 cases. The difference of gen-
der, age, duration, and severity among three groups are not
statistically significant (P[ 0.05).
Diagnosis Criteria
Referring to the 2007 diagnosis criteria made by the
cooperative experts group of inflammatory bowel diseases,
Digestive Disease Association of Chinese Medical Asso-
ciation [4].
Inclusion Criteria
Patients were included if they were satisfied with all of the
criteria:
• Meet the diagnostic criteria for ulcerative colitis by
colonoscopy exam 1 week before enrollment;
• Clinical types are active UC patients with chronic
relapsing;
• Mild-to-moderate UC patients;
• Aged 17–70 years old; and
• Signed informed consent.
Exclusion Criteria
Patients were excluded if they have any of: (1) Severe
primary diseases of cerebrovascular, liver, kidney, and
hematopoietic systems. (2) Serious complications, such as
partial stenosis, intestinal obstruction, intestinal perfora-
tion, rectal polyps, rectal distension toxic, colon, colorectal
cancer patients, and pregnant or lactating women.
Treatment
Patients in Group I received enema with Armillarisin
10 mg in saline 100 ml every night; Patients in Group II
received enema with Armillarisin 10 mg and dexametha-
sone 5 mg in saline 100 ml every night; Patients in Group
III received enema with dexamethasone 5 mg in saline
100 ml every night. The course of treatment was 4 weeks.
All patients underwent colonoscopy before treatment and
after treatment to evaluate the efficacy.
Outcome Measurements and Detection Methods
Aquantity of 5 ml fasting vein bloodwas taken before and after
treatment for each treatment group and for the control group.
The levels of serum IL-1b and IL-4 were measured using an
ELISA kit (Xitang Biotechnology Co., Ltd., Shanghai, China).
All procedures strictly followed the kit instruction
Efficacy Standards [4, 5]
• Cured clinical symptoms vanished and the mucosa
shows normal tissue by colonoscopy.
• Significant clinical symptoms vanished and the colon-
oscopy result shows that mucosa lesions are significant
improved.
• Effective clinical symptoms vanished and the colonos-
copy result shows mild inflammation of the mucosa or
false mucosal polyp formation.
• Ineffective the clinical symptoms and the endoscopic
and histological findings are not improved.
Statistics
All data were analyzed using SPSS 16.0 software (SPSS
Inc., Chicago, IL, United States). The numerical data were
presented using x s and tested using student t test. The
categorical data were tested using v2 test. P\ 0.05 indi-
cates significant statistic difference.
Results
The Comparison of Efficacy Among Three Groups
After 4 weeks of treatment, the total effective rate in Group
I is 90.0 %, the total effective rate in Group II is 95.0 %,
and in the control group, it is 70.0 %. The differences of
efficacy between Groups I and III, and between Groups II
and III are statistically significant (P\ 0.05) (Table 1).
The Comparison of the Levels of IL-4 and IL-1b Before
and After Treatment
The level of serum IL-4 was significantly increased after
4 weeks treatment, compared with the serum level before
treatment. The differences of the levels of IL-4 between the
treatment groups and the control group are statistically
significant (P\ 0.05) (Table 2). In comparison to the level
before treatment, the level of IL-1b was significantly
decreased after the treatment. The differences of the levels
of IL-1b between the treatment groups and the control
group are statistically significant (P\ 0.05) (Table 3).
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Discussion
The main clinical manifestations of UC are diarrhea,
abdominal pain, and mucus pus. UC is characteristic as
long duration, broad lesions, and seriously affecting the
quality of life of patients. This disease is considered to be
precancerous lesions of colon cancer and has been listed as
one of the modern diseases more difficult to cure by World
Health Organization. The etiology and pathogenesis of UC
are not entirely clear, but probably due to the autoimmune
damage, heredity, infection, and neuropsychiatric factors.
In recent years, the role of cytokines in treating UC is
increasing our attention. The roles of IL-1b, a pro-inflam-
matory cytokine, and IL-4, an anti-inflammatory cytokine,
have become increasingly clear. It turns out the occurrence
and development of UC probably because of the imbalance
between the two cytokines. During the occurrence and
development of UC, the local tissue generates a large
amount of IL-1b, which activates T lymphocytes and B
lymphocytes to enhance immune function. Meanwhile, IL-
1b promotes the expressions of other inflammatory cyto-
kines facilitating the neutrophil infiltration. In addition, the
occurrence of UC diarrhea probably is due to the fact that
IL-1b induces the release of H2O2, which impacts the
release of Ca2?, resulting in colonic smooth muscle dys-
function in UC patients [6].
IL-4 plays a key role in maintaining intestinal immunity
and the suppression and elimination of intestinal inflam-
mation [7]. IL-4 can inhibit the production of IL-1b from
monocyte-macrophage and reduce the ability of activated
monocytes macrophages secreting oxygen-free radicals.
Wenjie Yue and his colleagues found that the localized
expression level of IL-4 in UC intestinal mucosal lesions
was significantly higher than it in normal mucosa, indi-
cating that IL-4 is involved in the pathogenesis of UC.
They also found that in UC patients, the expression levels
of IL-4 in severe active group patients were significantly
higher than those patients in mild-to-moderate active
group, suggesting that the level of IL-4 increases with the
severity of the clinical disease activity increasing. There-
fore, the expression level of IL-4 can be used to assess the
severity of UC [8].
Armillarisin is a coumarin compound extracted from the
fruiting bodies of Armillariella, or artificially synthesized.
Armillarisin is mainly used for treating acute cholecystitis,
chronic cholecystitis attack, other biliary tract diseases
complicated by acute infection, chronic superficial gastri-
tis, and chronic atrophic gastritis superficial [9]. Mean-
while, Armillarisin plays a role in regulating and promoting
immune function and enhancing the role of macrophages.
As a result, Armillarisin inhibits bacteria growth, improves
the protein metabolism, and regulates liver function.
In this study, we used either Armillarisin alone or
Armillarisin combined with hormone therapy in treating
UC and found that after 4 weeks of treatment, the total
effective rate of Armillarisin in treating UC is 90.0 %. The
total effective rate of Armillarisin combined with hormone
therapy is 95.0 %. Both are significantly higher than the
70.0 % total effective rate of hormone therapy alone. The
serum level of anti-inflammatory cytokine IL-4 after
treatment is significantly higher than it before treatment.
Comparing to the levels of IL-4 after receiving hormone
therapy alone, the levels of IL-4 after receiving Armillar-
isin along or Armillarisin combined with hormone therapy
were significantly increased. The serum level of pro-
inflammatory cytokine IL-1b was significantly lower in the
Table 1 The comparison of effective rates among three groups (%)
Group n Cured Significant effective Effective Ineffective Total effective rate
Cases Rate Cases Rate Cases Rate Cases Rate
I 20 9 45.0 6 30.0 3 15.0 2 10.0 90.0
II 20 12 60.0 6 30.0 1 5.0 1 5.0 95.0
III 20 3 15.0 5 25.0 6 30.0 6 30.0 70.0
The differences of efficacy between Groups I and III, and between groups II and III
Table 2 The comparison of serum IL-4 before and after treatments
among three groups (x s, pg/ml)
Group n Before treatment After treatment
I 20 5.8 ± 2.1 12.2 ± 3.1**
II 20 6.1 ± 2.1 16.2 ± 4.1**
III 20 5.5 ± 4.1 8.2±2.3*
Compared to the level before treatment with group: * P\ 0.05;
Compared to Group III after treatment: ** P\ 0.05
Table 3 The comparison of serum IL-1 before and after treatments
among three groups (x s, ng/ml)
Group n Before treatment After treatment
I 20 1.3 ± 0.3 0.8 ± 0.2**
II 20 1.2 ± 0.2 0.6 ± 0.3**
III 20 1.4 ± 0.3 1.0±0.2*
Compared to the level before treatment with group: * P\ 0.05;
Compared to Group III after treatment: ** P\ 0.05
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treatment group in comparison to it in the control group.
Comparing to the levels of IL-1b in control group, its level
is also decreased significantly, suggesting that Armillarisin
is effective in treating UC. Meanwhile, we also found that
the efficacy of combined Armillarisin and hormone therapy
is also better than Armillarisin alone, indicating that a
combination of Armillarisin and hormone is better than
either Armillarisin or hormone therapy alone in treating
patients with UC.
In summary, in this study, we found Armillarisin has a
significant effect intreating UC. Furthermore, the better
efficacy might achieve by combining Armillarisin and
hormone therapy through increasing IL-4 and decreasing
IL-1b. The mechanism may be related to Armillarisin
regulating the body’s immunity. This study provides a
certain theoretical basis for the effective treatment of UC.
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